Jaguar Health (NASDAQ:JAGX) Shares Down 5%

Jaguar Health Inc (NASDAQ:JAGX)’s stock price traded down 5% during trading on Monday . The company traded as low as $0.70 and last traded at $0.67, 326,693 shares traded hands during mid-day trading. A decline of 70% from the average session volume of 1,096,455 shares. The stock had previously closed at $0.70.

A number of equities research analysts have recently commented on the stock. Zacks Investment Research lowered shares of Jaguar Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. ValuEngine raised shares of Jaguar Health from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. LADENBURG THALM/SH SH assumed coverage on shares of Jaguar Health in a research note on Thursday, September 12th. They issued a “buy” rating and a $5.00 price objective on the stock. Finally, HC Wainwright set a $10.00 price objective on shares of Jaguar Health and gave the company a “buy” rating in a research note on Tuesday, July 2nd.

The firm has a market capitalization of $34.92 million, a P/E ratio of 0.00 and a beta of 0.77. The company’s 50 day moving average is $1.18 and its 200-day moving average is $1.68. The company has a quick ratio of 0.24, a current ratio of 0.35 and a debt-to-equity ratio of 0.02.

Jaguar Health (NASDAQ:JAGX) last issued its earnings results on Wednesday, August 14th. The biotechnology company reported ($9.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($5.61) by ($3.48). The company had revenue of $1.71 million for the quarter, compared to the consensus estimate of $3.05 million. Jaguar Health had a negative return on equity of 698.61% and a negative net margin of 727.27%. On average, analysts predict that Jaguar Health Inc will post -5.44 EPS for the current fiscal year.

In related news, Director James J. Bochnowski bought 180,582 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were acquired at an average cost of $2.00 per share, with a total value of $361,164.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.81% of the stock is owned by corporate insiders.

About Jaguar Health (NASDAQ:JAGX)

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

Read More: Understanding the two types of arbitrage

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with's FREE daily email newsletter.